Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma
Primary Central Nervous System Lymphoma
ClinicalTrials.gov recordTREATMENT READING
Source sections for this topic, with the original link and date. Patient and professional reading are labelled separately.
Not medical advice · Not a complete treatment or trial directory
Made by Triangle.
Selected text from the National Cancer Institute, with the original link and date. Made by Triangle. This page is not an NCI PDQ summary. Source topics may be broader than an individual diagnosis.
Source: Primary Central Nervous System Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 13, 2025. Captured 2026-09-09.
Source: Primary Central Nervous System Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 13, 2025. Captured 2026-09-09.
Treatment options for primary CNS lymphoma include:
Induction therapy.
Sources: Induction therapy
Consolidation after induction therapy.
This page is made by Triangle. The reading above is selected source text, not a treatment recommendation, and it is not medical advice.
Source: Primary Central Nervous System Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 13, 2025. Captured 2026-09-09.
Trials using chemotherapy alone were justified because of the unsatisfactory results of using whole-brain radiation therapy (WBRT) alone [1,2] and significant neurological toxicity using high-dose methotrexate or other chemotherapeutic agents that cross the blood-brain barrier in combination with WBRT.[3-5]
Severe, delayed, neurological toxic effects were rarely seen in chemotherapy-only trials in the absence of subsequent radiation therapy. However, salvage radiation can be given for relapsed or refractory disease, sometimes at reduced dosage.[6,7]
Numerous phase I and phase II studies over two decades established the following active drugs for induction therapy or for treatment of relapsing disease. The following drugs have been used as single agents and in combinations:
High-dose methotrexate.[8-13] Outside of clinical trials, high-dose methotrexate is the most frequently used standard induction therapy.[14] However, it is given to inpatients, and it is too toxic for patients with a creatinine clearance under 35 cc/min or for most patients older than 75 years.
Lenalidomide with rituximab.[15] When high-dose chemotherapy is not feasible, this is the most frequently used combination. Lenalidomide can be initiated at low doses (e.g., 5 mg daily, 21 out of 28 days) in patients with renal insufficiency.
Sources: 15
Temozolomide.[20]
Sources: 20
Procarbazine.[23]
Sources: 23
Vincristine.[23]
Sources: 23
Pomalidomide.[24]
Sources: 24
Nivolumab.[25]
Sources: 25
Evidence (chemotherapy with or without other therapy):
The International Extranodal Lymphoma Study Group evaluated three different induction combinations in 227 patients with newly diagnosed, HIV-negative primary CNS lymphoma. Patients were randomly assigned to receive high-dose methotrexate (HD MTX) + high-dose cytarabine (HDA) (group 1), HD MTX + HDA + rituximab (R) (group 2), or HD MTX + HDA + R + thiotepa (the MATRix regimen) (group 3).[26][Level of evidence A1]The groups were compared as follows:The OS rate favored the complete MATRix regimen in all comparisons.[26][Level of evidence A1]
Sources: 26 · Level of evidence A1 · 26 · Level of evidence A1
The International Extranodal Lymphoma Study Group evaluated three different induction combinations in 227 patients with newly diagnosed, HIV-negative primary CNS lymphoma. Patients were randomly assigned to receive high-dose methotrexate (HD MTX) + high-dose cytarabine (HDA) (group 1), HD MTX + HDA + rituximab (R) (group 2), or HD MTX + HDA + R + thiotepa (the MATRix regimen) (group 3).[26][Level of evidence A1]The groups were compared as follows:The OS rate favored the complete MATRix regimen in all comparisons.[26][Level of evidence A1]
With a median follow-up of 88 months, the overall survival (OS) rate was 21% for group 1, 37% for group 2, and 56% for group 3.
Group 1 versus group 2: hazard ratio (HR), 0.64; 95% confidence interval (CI), 0.41–0.99; P = .04.
Group 1 versus group 3: HR, 0.42; 95% CI, 0.24–0.64; P = .00005.
Group 2 versus group 3: HR, 0.66; 95% CI, 0.44–0.98; P = .04.
The 113 patients who attained a complete response, partial response, or stable disease were randomly assigned to 36 Gy whole-brain radiation therapy versus autologous stem cell transplant (SCT) after thiotepa + bic-chloroethylnitrosourea + carmustine (BCNU) conditioning. No significant differences were seen in 7-year progression-free survival (PFS) or OS in regard to consolidation in this phase II trial.[26][Level of evidence B1]
Sources: 26 · Level of evidence B1
The thiotepa + BCNU conditioning regimen was well tolerated by patients aged 60 to 70 years. It had improved tolerability compared with prior reports using the more intensive thiotepa + busulfan regimen.[26][Level of evidence D]
Sources: 26 · Level of evidence D
Patients who received the two-drug combination had a complete remission rate of 23% (interquartile range [IQR], 14%‒31%; HR, 0.46; 95% CI, 0.28‒0.74). Patients who received the three-drug combination had a complete remission rate of 30% (IQR, 21%‒42%; HR, 0.61; 95% CI, 0.40‒0.94). Patients who received the four-drug MATRix combination had a complete remission rate of 49% (95% CI, 38%‒60%).
The addition of rituximab and thiotepa to high-dose methotrexate plus cytarabine resulted in a significant improvement in complete response, PFS, and OS.[26][Level of evidence A1]
Sources: 26 · Level of evidence A1
In a randomized, nonblinded multicenter trial, 79 patients were assigned to receive high-dose methotrexate with or without cytarabine.[27][Level of evidence B1]
Sources: 27 · Level of evidence B1
In a randomized, nonblinded multicenter trial, 79 patients were assigned to receive high-dose methotrexate with or without cytarabine.[27][Level of evidence B1]
The 3-year PFS rate was better for patients who received the two-drug regimen (HR, 0.54; 95% CI, 0.31–0.92; P = .01).
There was no statistical difference in the 3-year OS rate (46% for the two-drug regimen vs. 32% for the one-drug regimen; HR, 0.65; 95% CI, 0.38–1.13; P = .07).
This trial was the basis for setting the combination of high-dose methotrexate and high-dose cytarabine as the control arm in the MATRix trial.
In a randomized, prospective, multicenter trial, 200 patients were assigned to receive intravenous high-dose methotrexate, carmustine, teniposide, and oral prednisone with or without rituximab.[28][Level of evidence B1]
Sources: 28 · Level of evidence B1
In a randomized, prospective, multicenter trial, 200 patients were assigned to receive intravenous high-dose methotrexate, carmustine, teniposide, and oral prednisone with or without rituximab.[28][Level of evidence B1]
With a median follow-up of 32.9 months, there was no difference in the 1-year event-free survival (EFS) rate: 52% with rituximab (95% CI, 42%−61%) and 49% without rituximab (95% CI, 39%−58%; HR, 1.00; 95% CI, 0.70−1.43; P = .99).
Several other combination induction regimens were created empirically and presented as phase II trials.[29][Level of evidence C3]
Sources: 29 · Level of evidence C3
Several other combination induction regimens were created empirically and presented as phase II trials.[29][Level of evidence C3]
Rituximab + high-dose methotrexate + procarbazine + vincristine (R-MPV) (objective response rate, 97%; complete response, 66%)[23].
Sources: 23
High-dose methotrexate + rituximab + temozolomide (HD MTX + R + TEM) (objective response rate, 80%; complete response, 66%).[20]
Sources: 20
High-dose methotrexate ± rituximab (HD MTX ± R) + other chemotherapy (retrospective analysis of 885 patients) (objective response rate, 59%; complete response, 50%).[29]
Sources: 29
Summary
High-dose methotrexate regimens delivered with rituximab and other chemotherapeutic agents is used for induction therapy. The MATRix regimen described above has become one such standard based on randomized OS benefit with a four-drug regimen versus a two-drug or a three-drug regimen.[26][Level of evidence 1A] The MATRix regimen has never been compared with some of the other combination therapies mentioned above. A meta-analysis of rituximab randomized trials found improved PFS with the addition of rituximab (HR, 0.65; 95% CI, 0.45–0.95) but no difference in OS.[30][Level of evidence B2]
Sources: 26 · Level of evidence 1A · 30 · Level of evidence B2
Source: Primary Central Nervous System Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 13, 2025. Captured 2026-09-09.
Source: Primary Central Nervous System Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 13, 2025. Captured 2026-09-09.
Evidence (consolidation therapy with or without WBRT):
In a prospective, randomized, phase II trial, 87 patients (median age, 59–66 years) had induction therapy with high-dose methotrexate + high-dose cytarabine + rituximab + procarbazine + vincristine. Afterward, 37 patients had consolidation therapy with low-dose WBRT at 23.4 Gy.[31]
Sources: 31
In a prospective, randomized, phase II trial, 87 patients (median age, 59–66 years) had induction therapy with high-dose methotrexate + high-dose cytarabine + rituximab + procarbazine + vincristine. Afterward, 37 patients had consolidation therapy with low-dose WBRT at 23.4 Gy.[31]
With a median follow-up of 55 months, the 2-year intention-to-treat PFS was 78% with low-dose WBRT versus 54% without low-dose WBRT (HR, 0.51; P = .015).[31][Level of evidence B1]
Sources: 31 · Level of evidence B1
Investigator-assessed neurotoxicity was less than 15% in each arm and not significantly different. Another small phase II trial that examined low-dose WBRT at 23.4 Gy also found no increased problems seen on neuropsychological testing.[32,33]
In a prospective, randomized, phase II trial of 97 newly diagnosed patients who received high-dose methotrexate combination therapy for induction, patients were randomly assigned to receive WBRT at 40 Gy versus autologous SCT.[34]
Sources: 34
In a prospective, randomized, phase II trial of 97 newly diagnosed patients who received high-dose methotrexate combination therapy for induction, patients were randomly assigned to receive WBRT at 40 Gy versus autologous SCT.[34]
With a median follow-up of 8 years, deterioration of balance was significantly greater for patients who received WBRT versus patients who received autologous SCT (52% vs. 10%, P ≤ .001). Worsening neurocognition was also greater for patients who received WBRT (64% vs. 13%, P < .001).
The 8-year EFS rate was 67% for patients who received autologous SCT versus 39% for patients who received WBRT (HR, 0.13; P < .001). There was no significant difference in OS (69% for autologous SCT vs. 54% for WBRT).[34][Level of evidence B1]
Sources: 34 · Level of evidence B1
The authors concluded that 40 Gy WBRT should be avoided in first-line treatment because of its neurotoxicity and inferior efficacy.
In a prospective, randomized trial of 551 immunocompetent patients with newly diagnosed primary CNS lymphoma, all patients received induction chemotherapy with six cycles of high-dose methotrexate (4 g/m2) with or without ifosfamide. After chemotherapy was completed, responders were randomly assigned to receive either WBRT (45 Gy) or no treatment for complete-response patients and cytarabine for partial-response patients.[35]
Sources: 35
In a prospective, randomized trial of 551 immunocompetent patients with newly diagnosed primary CNS lymphoma, all patients received induction chemotherapy with six cycles of high-dose methotrexate (4 g/m2) with or without ifosfamide. After chemotherapy was completed, responders were randomly assigned to receive either WBRT (45 Gy) or no treatment for complete-response patients and cytarabine for partial-response patients.[35]
There was no statistical difference in median OS at 32.4 months for patients who received WBRT versus at 37.1 months for those who did not receive WBRT (HR, 1.06; 95% CI, 0.80–1.40; P = .71).[35][Level of evidence A1]
Sources: 35 · Level of evidence A1
Treatment-related neurotoxic effects were significantly worse in the WBRT arm.
In a prospective, randomized trial, 410 immunocompetent patients with newly diagnosed primary CNS lymphoma were scheduled to receive high-dose methotrexate. Patients were randomly assigned to receive either WBRT or no radiation therapy.[36]
Sources: 36
In a prospective, randomized trial, 410 immunocompetent patients with newly diagnosed primary CNS lymphoma were scheduled to receive high-dose methotrexate. Patients were randomly assigned to receive either WBRT or no radiation therapy.[36]
In the intent-to-treat population, WBRT was associated with longer PFS at 15.4 months versus 9.9 months (HR, 0.79; 95% CI, 0.64–0.98; P = .034). There was no difference in OS at 32.4 months versus 36.1 months (HR, 0.98; 95% CI, 0.79–1.26; P = .98).[36][Level of evidence B1]
Sources: 36 · Level of evidence B1
Long-term treatment-related neurotoxic effects were not reported, and the induction chemotherapy would now be considered substandard.
Summary
The significant neurotoxicity of standard-dose WBRT [37] has reduced its role to short-duration disease control at relapse, when the expected survival is short enough that the benefit outweighs the longer-term neurological consequences. For patients unable to undergo consolidation with autologous SCT due to age, performance status, or comorbidities, low-dose WBRT (23.4 Gy) would be a consolidation option.
Sources: 37
Source: Primary Central Nervous System Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 13, 2025. Captured 2026-09-09.
Evidence (consolidation therapy with or without autologous SCT):
In a prospective, randomized trial published in abstract form, 346 patients with newly diagnosed primary CNS lymphoma (patients aged 65 years and younger and patients aged 66–70 years with a performance status of 2 or lower) underwent induction therapy with 4 cycles of rituximab, high-dose methotrexate, high-dose cytarabine, and thiotepa (IELSG43 [NCT02531841]). Eighty-six patients discontinued treatment due to toxicity or progression. Of the 260 patients who completed induction therapy, 229 patients were randomly assigned to receive either chemotherapy consolidation with rituximab, dexamethasone, etoposide, ifosfamide, and carboplatin (n = 115) or autologous SCT using BCNU and thiotepa (n = 114).[38][Level of evidence A1]
Sources: IELSG43 · 38 · Level of evidence A1
In a prospective, randomized trial published in abstract form, 346 patients with newly diagnosed primary CNS lymphoma (patients aged 65 years and younger and patients aged 66–70 years with a performance status of 2 or lower) underwent induction therapy with 4 cycles of rituximab, high-dose methotrexate, high-dose cytarabine, and thiotepa (IELSG43 [NCT02531841]). Eighty-six patients discontinued treatment due to toxicity or progression. Of the 260 patients who completed induction therapy, 229 patients were randomly assigned to receive either chemotherapy consolidation with rituximab, dexamethasone, etoposide, ifosfamide, and carboplatin (n = 115) or autologous SCT using BCNU and thiotepa (n = 114).[38][Level of evidence A1]
With a median follow-up of 44 months, the 3-year OS rate was 86% (78%–91%) for autologous SCT versus 71% (61%–78%) for chemotherapy alone (HR, 0.47; P = .01).[38][Level of evidence A1]
Sources: 38 · Level of evidence A1
The 3-year PFS rate was 79% (71%–86%) for autologous SCT versus 53% (43%–62%) for chemotherapy alone.
There was no negative effect on neurocognitive function in either arm in the absence of progression.
This was the first randomized trial establishing a survival advantage for newly diagnosed patients receiving autologous SCT who are young enough and healthy enough to endure this aggressive approach.
In a prospective, randomized, phase II trial, 97 newly diagnosed patients receiving high-dose methotrexate combination therapy for induction were randomly assigned to receive WBRT at 40 Gy or autologous SCT.[34]
Sources: 34
In a prospective, randomized, phase II trial, 97 newly diagnosed patients receiving high-dose methotrexate combination therapy for induction were randomly assigned to receive WBRT at 40 Gy or autologous SCT.[34]
With a median follow-up of 8 years, deterioration of balance was significantly greater for patients who received WBRT than for patients who received autologous SCT (52% vs. 10%, P ≤ .001). Worsening neurocognition was also greater for patients who received WBRT (64% vs. 13%, P < .001).
The 8-year EFS rate was 67% for patients who received autologous SCT versus 39% for patients who received WBRT (HR, 0.13; P < .001). There was no difference in OS (69% for autologous SCT vs. 65% for WBRT).[34][Level of evidence B1]
Sources: 34 · Level of evidence B1
The authors concluded that 40 Gy WBRT should be avoided in first-line treatment because of its neurotoxicity and inferior efficacy.
A prospective, randomized, phase II trial included newly diagnosed patients aged 75 years and younger. Patients received intensive induction therapy with high-dose methotrexate at 8 g/m2 every 2 weeks, temozolomide, rituximab, and high-dose cytarabine. Patients were randomly assigned at the start of therapy to consolidation with thiotepa + BCNU conditioning with autologous SCT or nonmyeloablative therapy with high-dose cytarabine with a 46-hour infusion of etoposide (EA).[39]
Sources: 39
A prospective, randomized, phase II trial included newly diagnosed patients aged 75 years and younger. Patients received intensive induction therapy with high-dose methotrexate at 8 g/m2 every 2 weeks, temozolomide, rituximab, and high-dose cytarabine. Patients were randomly assigned at the start of therapy to consolidation with thiotepa + BCNU conditioning with autologous SCT or nonmyeloablative therapy with high-dose cytarabine with a 46-hour infusion of etoposide (EA).[39]
With a median follow-up of 3.8 years, the median PFS was 6 years (95% CI, 3.9–not reached [NR]) for autologous SCT versus 2.4 years (95% CI, 0.6–NR) for EA (P = .02).[39][Level of evidence B1]
Sources: 39 · Level of evidence B1
PFS from the time of consolidation was not statistically different (HR, 0.58; 95% CI, 0.25–1.36; P = .21).
There was no statistically significant difference in the 3-year OS rate: 83% (69%–91%) for autologous SCT and 72% (57%–82%) for EA.
This trial showed the limitations of induction therapy, which affected the impact of consolidation therapy.
Several phase II studies evaluated consolidation with intensive chemotherapy supported by autologous SCT.[19,20,23,40-43] This approach is appropriate for patients aged 80 years and under with few comorbidities, good performance status, and an adequate response to induction therapy.
Summary
Consolidation therapy with autologous SCT results in an OS advantage for newly diagnosed patients with good performance status, few comorbidities, and an adequate response to induction therapy (in this case, the MATRix regimen: high-dose methotrexate, high-dose cytarabine, rituximab, and temozolomide).[39] For patients unable to proceed to autologous SCT, consolidation with low-dose WBRT (32.4 Gy) or nonmyeloablative therapy might be considered.
Sources: 39
Source: Primary Central Nervous System Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 13, 2025. Captured 2026-09-09.
Source: Primary Central Nervous System Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 13, 2025. Captured 2026-09-09.
The prognosis for patients with recurrent CNS lymphoma is poor, with a median survival of 6 to 12 months, but up to 43 to 50 months if autologous stem cell transplant (SCT) consolidation is performed (if not applied previously).[1] This finding implies that deferred autologous SCT until first relapse may still result in longer-term survival. The prognosis is worse for patients 60 years and older, who account for more than 50% of cases.[2]
Treatment options for recurrent primary CNS lymphoma include:
Reinduction therapy followed by SCT.
Sources: Reinduction therapy followed by SCT
Source: Primary Central Nervous System Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 13, 2025. Captured 2026-09-09.
Patients with recurrence after high-dose methotrexate-based combination chemotherapy may try autologous SCT consolidation after reinduction of remission with single-agent or combination therapy from the following options:[3]
Sources: 3
Rituximab + lenalidomide.[4]
Sources: 4
Rituximab + lenalidomide + ibrutinib.[5]
Sources: 5
Rituximab.[6]
Sources: 6
Ibrutinib.[7]
Sources: 7
Temozolomide.
Chimeric antigen receptor (CAR) T cells.
DA-TEDDI-R: temozolomide, etoposide, liposomal doxorubicin, dexamethasone, ibrutinib, and rituximab (under clinical evaluation).
Patients deemed ineligible for transplant can receive palliative care with these agents.
Evidence (reinduction therapy):
A phase I/II clinical trial evaluated CD19-directed CAR T-cell therapy using tisagenlecleucel in patients with relapsed primary CNS lymphoma.[8][Level of evidence C3]CAR T-cell therapy provides an option for patients with relapsed primary CNS lymphoma.[8]
Sources: 8 · Level of evidence C3 · 8
A phase I/II clinical trial evaluated CD19-directed CAR T-cell therapy using tisagenlecleucel in patients with relapsed primary CNS lymphoma.[8][Level of evidence C3]CAR T-cell therapy provides an option for patients with relapsed primary CNS lymphoma.[8]
One-half of the patients (6 of 12) had a complete response.
Three patients maintained a complete response at 9 months, 12 months, and 23 months at the time of data cutoff.
Five patients had low-grade immune cell–assisted neurotoxicity.
One patient had grade 3 neurotoxicity.
The DA-TEDDI-R regimen incorporates temozolomide, etoposide, liposomal doxorubicin, dexamethasone, ibrutinib, and rituximab.[7][Level of evidence C3] Further studies of this regimen are under way (NCT03964090 and NCT02203526). Dexamethasone should be avoided with ibrutinib single agent or combination therapy due to the risk of serious fungal infections. This approach requires access to intravenous antifungal agents not available outside of a clinical trial. By eliminating dexamethasone and ibrutinib, the other drugs may be used together with less risk of fungal infections.
Sources: 7 · Level of evidence C3 · NCT03964090 · NCT02203526
The DA-TEDDI-R regimen incorporates temozolomide, etoposide, liposomal doxorubicin, dexamethasone, ibrutinib, and rituximab.[7][Level of evidence C3] Further studies of this regimen are under way (NCT03964090 and NCT02203526). Dexamethasone should be avoided with ibrutinib single agent or combination therapy due to the risk of serious fungal infections. This approach requires access to intravenous antifungal agents not available outside of a clinical trial. By eliminating dexamethasone and ibrutinib, the other drugs may be used together with less risk of fungal infections.
Among 18 patients who received this regimen (five previously untreated), the complete remission rate was 86%, but high rates (39%) of invasive aspergillosis were reported.
In a phase II study, patients with relapsed or refractory primary CNS lymphoma were treated with rituximab plus lenalidomide.[4][Level of evidence C3]
Sources: 4 · Level of evidence C3
In a phase II study, patients with relapsed or refractory primary CNS lymphoma were treated with rituximab plus lenalidomide.[4][Level of evidence C3]
An overall response rate of 36% was reported.
Source: Primary Central Nervous System Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 13, 2025. Captured 2026-09-09.
Retrospective reviews of selected patients with primary intraocular lymphoma and no evidence of disseminated central nervous system (CNS) disease showed that localized therapy with intraocular methotrexate or ocular radiation therapy or systemic therapy with rituximab were effective in clearing lymphoma cells from the eye. However, most patients had subsequent CNS relapse.[1,2][Level of evidence C3] Anecdotal series reported lower relapse rates when high-dose methotrexate was added, but prospective multicenter trials with even retrospective controls do not exist.[1,2][Level of evidence D]
Sources: 1 · 2 · Level of evidence C3 · 1 · 2 · Level of evidence D
Relapsing disease in the rest of the CNS is treated with the same options listed for primary CNS lymphoma in the brain. In a phase III randomized study of whole-brain radiation therapy, patients with intraocular disease and concomitant brain involvement had a worse prognosis than those with brain involvement alone (19 patients with both, 391 patients with brain involvement only).[3]
Sources: 3
Source: Primary Central Nervous System Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 13, 2025. Captured 2026-09-09.
These references have been identified by members of the PDQ Adult Treatment Editorial Board as significant in the field of primary central nervous system (CNS) lymphoma treatment. This list is provided to inform users of important studies that have helped shape the current understanding of and treatment options for primary CNS lymphoma. Listed after each reference are the sections within this summary where the reference is cited.
Sources: PDQ Adult Treatment Editorial Board
Ferreri AJ, Illerhaus G: The role of autologous stem cell transplantation in primary central nervous system lymphoma. Blood 127 (13): 1642-9, 2016. [PUBMED Abstract]Cited in:
Sources: [PUBMED Abstract]
Ferreri AJ, Illerhaus G: The role of autologous stem cell transplantation in primary central nervous system lymphoma. Blood 127 (13): 1642-9, 2016. [PUBMED Abstract]Cited in:
Treatment of Primary CNS Lymphoma.
Sources: Treatment of Primary CNS Lymphoma
Korfel A, Thiel E, Martus P, et al.: Randomized phase III study of whole-brain radiotherapy for primary CNS lymphoma. Neurology 84 (12): 1242-8, 2015. [PUBMED Abstract]Cited in:
Sources: [PUBMED Abstract]
Korfel A, Thiel E, Martus P, et al.: Randomized phase III study of whole-brain radiotherapy for primary CNS lymphoma. Neurology 84 (12): 1242-8, 2015. [PUBMED Abstract]Cited in:
Treatment of Primary CNS Lymphoma.
Sources: Treatment of Primary CNS Lymphoma
Treatment of Intraocular Lymphoma.
Sources: Treatment of Intraocular Lymphoma
Thiel E, Korfel A, Martus P, et al.: High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. Lancet Oncol 11 (11): 1036-47, 2010. [PUBMED Abstract]Cited in:
Sources: [PUBMED Abstract]
Thiel E, Korfel A, Martus P, et al.: High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. Lancet Oncol 11 (11): 1036-47, 2010. [PUBMED Abstract]Cited in:
Treatment of Primary CNS Lymphoma.
Sources: Treatment of Primary CNS Lymphoma
Source: Primary CNS Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 25, 2023. Captured 2026-09-09.
The prognosis depends on the following:
Sources: prognosis
Whether the patient has HIV.
The patient's age and general health.
Whether the tumor is in the central nervous system, eye, or both.
The level of certain substances in the blood and cerebrospinal fluid (CSF).
Treatment options depend on the following:
Whether the tumor is in the central nervous system, eye, or both.
The patient's age and general health.
Whether the cancer has just been diagnosed or has recurred (come back).
Sources: recurred
Treatment of primary CNS lymphoma works best when the tumor has not spread outside the cerebrum (the largest part of the brain) and the patient is younger than 60 years, able to carry out most daily activities, and does not have AIDS or other diseases that weaken the immune system.
Sources: cerebrum
Source: Primary CNS Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 25, 2023. Captured 2026-09-09.
Primary CNS lymphoma often recurs in the brain, spinal cord, or the eye.
Sources: recurs · brain · spinal cord
Source: Primary CNS Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 25, 2023. Captured 2026-09-09.
Source: Primary CNS Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 25, 2023. Captured 2026-09-09.
There are different types of treatment for patients with primary central nervous system (CNS) lymphoma.
The following types of treatments are used:
The following types of treatments are used:
Radiation therapy
Chemotherapy
Steroid therapy
Targeted therapy
High-dose chemotherapy with stem cell transplant
Immunotherapy
New types of treatment are being tested in clinical trials.
Treatment for primary CNS lymphoma may cause side effects.
Patients may want to think about taking part in a clinical trial.
Patients can enter clinical trials before, during, or after starting their cancer treatment.
Follow-up tests may be needed.
Source: Primary CNS Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 25, 2023. Captured 2026-09-09.
Different types of treatment are available for patients with primary CNS lymphoma. Some treatments are standard (the currently used treatment), and some are being tested in clinical trials. A treatment clinical trial is a research study meant to help improve current treatments or obtain information on new treatments for patients with cancer. When clinical trials show that a new treatment is better than the standard treatment, the new treatment may become the standard treatment. Patients may want to think about taking part in a clinical trial. Some clinical trials are open only to patients who have not started treatment.
Sources: primary CNS lymphoma · standard · clinical trials · research study · cancer
Surgery is not used to treat primary CNS lymphoma.
Sources: Surgery
Source: Primary CNS Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 25, 2023. Captured 2026-09-09.
Source: Primary CNS Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 25, 2023. Captured 2026-09-09.
Radiation therapy is a cancer treatment that uses high-energy x-rays or other types of radiation to kill cancer cells or keep them from growing. External radiation therapy uses a machine outside the body to send radiation toward the area of the body with cancer. Because primary CNS lymphoma spreads throughout the brain, external radiation therapy is given to the whole brain. This is called whole-brain radiation therapy.
Sources: Radiation therapy · x-rays · radiation · cells · External radiation therapy · brain · whole-brain radiation therapy
High-dose radiation therapy to the brain can damage healthy tissue and cause disorders that can affect thinking, learning, problem solving, reading, writing, speech, and memory. Clinical trials have tested the use of chemotherapy alone or before radiation therapy to reduce the damage to healthy brain tissue that occurs with the use of radiation therapy.
Sources: dose · tissue · disorders · chemotherapy
Source: Primary CNS Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 25, 2023. Captured 2026-09-09.
Chemotherapy is a cancer treatment that uses drugs to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. When chemotherapy is taken by mouth or injected into a vein or muscle, the drugs enter the bloodstream and can reach cancer cells throughout the body (systemic chemotherapy). When chemotherapy is placed directly into the cerebrospinal fluid (intrathecal chemotherapy), an organ, or a body cavity such as the abdomen, the drugs mainly affect cancer cells in those areas (regional chemotherapy).
Sources: drugs · injected · vein · bloodstream · systemic chemotherapy · cerebrospinal fluid · intrathecal chemotherapy · organ · cavity · abdomen · regional chemotherapy
The way the chemotherapy is given depends on where the tumor is in the CNS or eye. Primary CNS lymphoma may be treated with systemic chemotherapy, intrathecal chemotherapy, and/or intraventricular chemotherapy, in which anticancer drugs are placed into the ventricles (fluid-filled cavities) of the brain. If primary CNS lymphoma is found in the eye, anticancer drugs are injected directly into the vitreous humor (jelly-like substance) inside the eye.
Sources: tumor · CNS · intraventricular · ventricles · fluid · vitreous humor
Source: Primary CNS Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 25, 2023. Captured 2026-09-09.
Steroids are hormones made naturally in the body. They can also be made in a laboratory and used as drugs. Glucocorticoids are steroid drugs that have an anticancer effect in lymphomas.
Sources: Steroids · hormones · Glucocorticoids · steroid drugs · lymphomas
Source: Primary CNS Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 25, 2023. Captured 2026-09-09.
Targeted therapy is a type of treatment that uses drugs or other substances to identify and attack specific cancer cells.
Sources: Targeted therapy
Monoclonal antibodies: Monoclonal antibodies are immune system proteins made in the laboratory to treat many diseases, including cancer. As a cancer treatment, these antibodies can attach to a specific target on cancer cells or other cells that may help cancer cells grow. The antibodies are able to then kill the cancer cells, block their growth, or keep them from spreading. Monoclonal antibodies are given by infusion. They may be used alone or to carry drugs, toxins, or radioactive material directly to cancer cells. Rituximab and nivolumab are types of monoclonal antibodies used to treat newly diagnosed or recurrent primary CNS lymphoma.
Sources: Monoclonal antibodies · immune system · proteins · antibodies · infusion · toxins · radioactive · Rituximab · nivolumab · diagnosed · recurrent
Tyrosine kinase inhibitors: These small-molecule drugs go through the cell membrane and work inside cancer cells to block signals that cancer cells need to grow and divide. Ibrutinib is a type of tyrosine kinase inhibitor used to treat newly diagnosed or recurrent primary CNS lymphoma.
Sources: Tyrosine kinase inhibitors · small-molecule drugs · membrane · Ibrutinib
Source: Primary CNS Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 25, 2023. Captured 2026-09-09.
High doses of chemotherapy are given to kill cancer cells. Healthy cells, including blood-forming cells, are also destroyed by the cancer treatment. Stem cell transplant is a treatment to replace the blood-forming cells. Stem cells (immature blood cells) are removed from the blood or bone marrow of the patient or a donor and are frozen and stored. After the patient completes chemotherapy, the stored stem cells are thawed and given back to the patient through an infusion. These reinfused stem cells grow into (and restore) the body's blood cells.
Sources: blood · Stem cell transplant · Stem cells · bone marrow · donor
Source: Primary CNS Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 25, 2023. Captured 2026-09-09.
Immunotherapy is a treatment that uses the patient's immune system to fight cancer. Substances made by the body or made in a laboratory are used to boost, direct, or restore the body's natural defenses against cancer.
Sources: Immunotherapy
CAR T-cell therapy: This treatment changes the patient's T cells (a type of immune system cell) so they will attack certain proteins on the surface of cancer cells. T cells are taken from the patient, and special receptors are added to their surface in the laboratory. The changed cells are called chimeric antigen receptor (CAR) T cells. The CAR T cells are grown in the laboratory and given to the patient by infusion. The CAR T cells multiply in the patient's blood and attack cancer cells.
Sources: CAR T-cell therapy · T cells · receptors · chimeric antigen receptor
Source: Primary CNS Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 25, 2023. Captured 2026-09-09.
Information about clinical trials is available from the NCI website.
Sources: NCI website
Source: Primary CNS Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 25, 2023. Captured 2026-09-09.
For information about side effects caused by treatment for cancer, visit our Side Effects page.
Sources: side effects · Side Effects
Source: Primary CNS Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 25, 2023. Captured 2026-09-09.
For some patients, taking part in a clinical trial may be the best treatment choice. Clinical trials are part of the cancer research process. Clinical trials are done to find out if new cancer treatments are safe and effective or better than the standard treatment.
Sources: clinical trial · standard treatment
Many of today's standard treatments for cancer are based on earlier clinical trials. Patients who take part in a clinical trial may receive the standard treatment or be among the first to receive a new treatment.
Patients who take part in clinical trials also help improve the way cancer will be treated in the future. Even when clinical trials do not lead to effective new treatments, they often answer important questions and help move research forward.
Source: Primary CNS Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 25, 2023. Captured 2026-09-09.
Some clinical trials only include patients who have not yet received treatment. Other trials test treatments for patients whose cancer has not gotten better. There are also clinical trials that test new ways to stop cancer from recurring (coming back) or reduce the side effects of cancer treatment.
Sources: side effects
Clinical trials are taking place in many parts of the country. Information about clinical trials supported by NCI can be found on NCI’s clinical trials search webpage. Clinical trials supported by other organizations can be found on the ClinicalTrials.gov website.
Sources: clinical trials search · ClinicalTrials.gov
Source: Primary CNS Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 25, 2023. Captured 2026-09-09.
As you go through treatment, you will have follow-up tests or check-ups. Some tests that were done to diagnose or stage the cancer may be repeated to see how well the treatment is working. Decisions about whether to continue, change, or stop treatment may be based on the results of these tests.
Some of the tests will continue to be done from time to time after treatment has ended. The results of these tests can show if your condition has changed or if the cancer has recurred (come back).
Source: Primary CNS Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 25, 2023. Captured 2026-09-09.
For information about the treatments listed below, see the Treatment Option Overview section.
Sources: Treatment Option Overview
Treatment of newly diagnosed primary central nervous system (CNS) lymphoma may include the following:
Sources: diagnosed · primary central nervous system (CNS) lymphoma
Whole-brain radiation therapy.
Sources: Whole-brain radiation therapy
Chemotherapy with or without radiation therapy.
Sources: Chemotherapy · radiation therapy
Targeted therapy alone (rituximab, nivolumab, or ibrutinib).
Sources: Targeted therapy · rituximab · nivolumab · ibrutinib
Targeted therapy (rituximab) and chemotherapy.
High-dose chemotherapy and stem cell transplant.
Sources: High-dose chemotherapy · stem cell transplant
A clinical trial of high-dose chemotherapy followed by whole-brain radiation therapy, stem cell transplant, and/or targeted therapy.
Sources: clinical trial
A clinical trial of chemotherapy with or without stem cell transplant.
A clinical trial of targeted therapy (rituximab and ibrutinib) and chemotherapy.
Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.
Sources: clinical trial search · General information
Source: Primary CNS Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 25, 2023. Captured 2026-09-09.
For information about the treatments listed below, see the Treatment Option Overview section.
Sources: Treatment Option Overview
Treatment of recurrent primary central nervous system (CNS) lymphoma may include the following:
Sources: recurrent · primary central nervous system (CNS) lymphoma
Chemotherapy.
Sources: Chemotherapy
Targeted therapy (rituximab, nivolumab, or ibrutinib).
Sources: Targeted therapy · rituximab · nivolumab · ibrutinib
Stem cell transplant.
Sources: Stem cell transplant
CAR T-cell therapy.
Sources: CAR T-cell therapy
Radiation therapy (if not received in earlier treatment).
Sources: Radiation therapy
A clinical trial of targeted therapy (rituximab and ibrutinib) and chemotherapy.
Sources: clinical trial
Source: Primary CNS Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 25, 2023. Captured 2026-09-09.
For information about the treatments listed below, see the Treatment Option Overview section.
Sources: Treatment Option Overview
Treatment of newly diagnosed primary intraocular lymphoma may include the following:
Sources: diagnosed · intraocular · lymphoma
Chemotherapy (intraocular or systemic) with or without radiation therapy.
Sources: Chemotherapy · systemic · radiation therapy
Whole-brain radiation therapy.
Sources: Whole-brain radiation therapy
Chemotherapy with targeted therapy (rituximab).
Sources: targeted therapy · rituximab
Primary Central Nervous System Lymphoma
ClinicalTrials.gov recordDiffuse Large B-cell-lymphoma
ClinicalTrials.gov recordCentral Nervous System Lymphoma, Secondary Central Nervous System Lymphoma
ClinicalTrials.gov recordLymphoma
ClinicalTrials.gov recordLymphoma
ClinicalTrials.gov recordCentral Nervous System Lymphoma, Malignant Glioma, Metastatic Malignant Neoplasm in the Brain
ClinicalTrials.gov recordAccelerated Phase Chronic Myelogenous Leukemia, Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission,...
ClinicalTrials.gov recordAIDS-Related-Primary Central Nervous System Lymphoma
ClinicalTrials.gov recordLymphoma
ClinicalTrials.gov recordLymphoma
ClinicalTrials.gov recordLymphoma
ClinicalTrials.gov recordCentral Nervous System Lymphoma
ClinicalTrials.gov recordChemotherapeutic Agent Toxicity, Cognitive/Functional Effects, Lymphoma, Neurotoxicity, Radiation Toxicity
ClinicalTrials.gov recordPrimary Central Nervous System Lymphoma
ClinicalTrials.gov recordLymphoma, Primary Central Nervous System Lymphoma, Recurrent/Refractory Secondary Central Nervous System Lymphoma
ClinicalTrials.gov recordLymphoma
ClinicalTrials.gov recordNon-Hodgkin Lymphoma, Lymphoma, Diffuse Large B-Cell Lymphoma, Gray-zone Lymphoma, Primary Central Nervous System Lymphoma
ClinicalTrials.gov recordCentral Nervous System Lymphoma
ClinicalTrials.gov recordPrimary Central Nervous System Lymphoma
Treatment of Recurrent Primary Central Nervous System Lymphoma
GADAVIST is indicated for: Magnetic resonance imaging (MRI) of the central nervous system (CNS) to detect and visualize areas with disrupted blood brain barrier and/or abnormal vascularity in adult and pediatric patients including term...
DailyMed labelGADAVIST is indicated for: Magnetic resonance imaging (MRI) of the central nervous system (CNS) to detect and visualize areas with disrupted blood brain barrier and/or abnormal vascularity in adult and pediatric patients including term...
DailyMed labelGADAVIST is indicated for: Magnetic resonance imaging (MRI) of the central nervous system (CNS) to detect and visualize areas with disrupted blood brain barrier and/or abnormal vascularity in adult and pediatric patients including term...
DailyMed label